cx-2029
mAbexperimentalADC
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2018 (NCT03543813)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transferrin receptor protein 1INHIBITOR
TFRC inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- MMAE
Oral
No
Parenteral
No
Topical
No
Also known as
- cx-2029
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03543813 | Phase 1/Phase 2 (Phase 2) | Jun 15, 2018 | CytomX Therapeutics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CytomX Therapeutics | For profit | 1 | 1 | 1 | 2018 |
1 organizations
Page 1 / 1